These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 27503607)
1. Protease-Responsive Prodrug with Aggregation-Induced Emission Probe for Controlled Drug Delivery and Drug Release Tracking in Living Cells. Cheng Y; Huang F; Min X; Gao P; Zhang T; Li X; Liu B; Hong Y; Lou X; Xia F Anal Chem; 2016 Sep; 88(17):8913-9. PubMed ID: 27503607 [TBL] [Abstract][Full Text] [Related]
2. Dong Y; Du P; Liu P Int J Pharm; 2020 Oct; 588():119723. PubMed ID: 32755688 [TBL] [Abstract][Full Text] [Related]
3. Cell-Penetrating Doxorubicin Released from Elastin-Like Polypeptide Kills Doxorubicin-Resistant Cancer Cells in In Vitro Study. Ryu JS; Kratz F; Raucher D Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498762 [TBL] [Abstract][Full Text] [Related]
4. H Liang YX; Sun XY; Xu DZ; Huang JR; Tang Q; Lu ZL; Liu R Bioorg Chem; 2022 Feb; 119():105559. PubMed ID: 34952244 [TBL] [Abstract][Full Text] [Related]
5. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer. Peng ZH; Kopeček J J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409 [TBL] [Abstract][Full Text] [Related]
6. Polymeric prodrug microspheres with tumor intracellular microenvironment bioreducible degradation, pH-triggered "off-on" fluorescence and drug release for precise imaging-guided diagnosis and chemotherapy. Pei M; Li G; Ma K; Li J; Wang Y; Liu P Colloids Surf B Biointerfaces; 2019 May; 177():313-320. PubMed ID: 30771583 [TBL] [Abstract][Full Text] [Related]
7. Combretastatin A4 Nanodrug-Induced MMP9 Amplification Boosts Tumor-Selective Release of Doxorubicin Prodrug. Jiang J; Shen N; Ci T; Tang Z; Gu Z; Li G; Chen X Adv Mater; 2019 Nov; 31(44):e1904278. PubMed ID: 31549774 [TBL] [Abstract][Full Text] [Related]
8. Multifunctional Polymeric Prodrug with Simultaneous Conjugating Camptothecin and Doxorubicin for pH/Reduction Dual-Responsive Drug Delivery. Dong S; Sun Y; Liu J; Li L; He J; Zhang M; Ni P ACS Appl Mater Interfaces; 2019 Mar; 11(9):8740-8748. PubMed ID: 30693750 [TBL] [Abstract][Full Text] [Related]
9. Photo- and pH- Dual-Responsive β-Cyclodextrin-Based Supramolecular Prodrug Complex Self-Assemblies for Programmed Drug Delivery. Bai Y; Liu CP; Song X; Zhuo L; Bu H; Tian W Chem Asian J; 2018 Dec; 13(24):3903-3911. PubMed ID: 30311448 [TBL] [Abstract][Full Text] [Related]
10. Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy. Yoo J; Sanoj Rejinold N; Lee D; Jon S; Kim YC J Control Release; 2017 Oct; 264():89-101. PubMed ID: 28842316 [TBL] [Abstract][Full Text] [Related]
11. Probe-inspired nano-prodrug with dual-color fluorogenic property reveals spatiotemporal drug release in living cells. Xue X; Jin S; Zhang C; Yang K; Huo S; Chen F; Zou G; Liang XJ ACS Nano; 2015 Mar; 9(3):2729-39. PubMed ID: 25688453 [TBL] [Abstract][Full Text] [Related]
12. Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity. Zhang A; Yao L; An M Chem Commun (Camb); 2017 Nov; 53(95):12826-12829. PubMed ID: 29143021 [TBL] [Abstract][Full Text] [Related]
13. Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer. Bellavita R; Piccolo M; Leone L; Ferraro MG; Dardano P; De Stefano L; Nastri F; Irace C; Falanga A; Galdiero S Int J Nanomedicine; 2024; 19():6057-6084. PubMed ID: 38911501 [TBL] [Abstract][Full Text] [Related]
14. Enzyme-responsive cell-penetrating peptide conjugated mesoporous silica quantum dot nanocarriers for controlled release of nucleus-targeted drug molecules and real-time intracellular fluorescence imaging of tumor cells. Li J; Liu F; Shao Q; Min Y; Costa M; Yeow EK; Xing B Adv Healthc Mater; 2014 Aug; 3(8):1230-9. PubMed ID: 24550203 [TBL] [Abstract][Full Text] [Related]
15. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation. Desbène S; Van HD; Michel S; Koch M; Tillequin F; Fournier G; Farjaudon N; Monneret C Anticancer Drug Des; 1998 Dec; 13(8):955-68. PubMed ID: 10335269 [TBL] [Abstract][Full Text] [Related]
16. Rod-like cellulose nanocrystal/cis-aconityl-doxorubicin prodrug: A fluorescence-visible drug delivery system with enhanced cellular uptake and intracellular drug controlled release. Li N; Lu W; Yu J; Xiao Y; Liu S; Gan L; Huang J Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():179-189. PubMed ID: 30033244 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of a photoresponsive doxorubicin/combretastatin A4 hybrid prodrug. Liu W; Liang L; Zhao L; Tan H; Wu J; Qin Q; Gou X; Sun X Bioorg Med Chem Lett; 2019 Feb; 29(3):487-490. PubMed ID: 30553736 [TBL] [Abstract][Full Text] [Related]
18. H Dai YD; Sun XY; Sun W; Yang JB; Liu R; Luo Y; Zhang T; Tian Y; Lu ZL; He L Org Biomol Chem; 2019 Jun; 17(22):5570-5577. PubMed ID: 31114827 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Elastin-Like Polypeptides for Tumor Targeted Delivery of Doxorubicin to Glioblastoma. Dragojevic S; Mackey R; Raucher D Molecules; 2019 Sep; 24(18):. PubMed ID: 31489879 [TBL] [Abstract][Full Text] [Related]
20. Redox-responsive tetraphenylethylene-buried crosslinked vesicles for enhanced drug loading and efficient drug delivery monitoring. Yu Y; Chen Y; Huang J; Wang L; Gu Z; Zhang S J Mater Chem B; 2019 Dec; 7(47):7540-7547. PubMed ID: 31720682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]